Arsanis

Arsanis

Verifiedclosed
Addressing critical infectious disease threats with targeted monoclonal antibody immunotherapies

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues--4m----
Profit--(43m)----
% profit margin--(1075 %)----
  • Edit
DateInvestorsAmountRound
$400kEarly VC
$10mSeries A
€1.7mGrant
$20mSeries B
€50kGrant
$15mSeries C
N/ADebt
$9.3mGrant
$45.5mSeries D
N/A$40m
Valuation: $136m
IPO
Total Funding$102m

Recent News about Arsanis

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.